Showing results (21-30 of 53) with videos related to
Sort By:
Pageof 6
The Laryngoscope|September 28, 2002
In vivo characteristics of HPV-immortalized and carcinogen transformed oral keratinocytesGeorge H Yoo, Marie P Piechocki, Fulvio Lonardo, et al.The Laryngoscope|June 1, 2010
XRP6258-induced gene expression patterns in head and neck cancer carcinomaGeorge H Yoo, Zyed Kafri, John F Ensley, et al.Head & Neck|February 7, 2012
Up-front neck dissection followed by concurrent chemoradiation in patients with regionally advanced head and neck cancerPeter A Paximadis, Michael E Christensen, Greg Dyson, et al.International Journal of Cancer|June 9, 2004
Microsatellite analysis of serum DNA in patients with head and neck cancerHomaira Nawroz-Danish, Claus F Eisenberger, George H Yoo, et al.Archives of Otolaryngology--Head & Neck Surgery|September 23, 2009
A phase 2 trial of surgery with perioperative INGN 201 (Ad5CMV-p53) gene therapy followed by chemoradiotherapy for advanced, resectable squamous cell carcinoma of the oral cavity, oropharynx, hypopharynx, and larynx: report of the Southwest Oncology GroupGeorge H Yoo, James Moon, Michael Leblanc, et al.Cancer|January 30, 2002
The effects of exogenous p53 overexpression on HPV-immortalized and carcinogen transformed oral keratinocytesGeorge H Yoo, James Washington, Jeffrey Oliver, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 31, 2004
Organ preservation for advanced resectable cancer of the base of tongue and hypopharynx: a Southwest Oncology Group TrialSusan G Urba, James Moon, P G Shankar Giri, et al.The Laryngoscope|October 29, 2004
Enhancement of Ad-p53 therapy with docetaxel in head and neck cancerGeorge H Yoo, Marie P Piechocki, Jeffery Oliver, et al.Head & Neck|July 12, 2002
A multicenter phase II study of tgDCC-E1A for the intratumoral treatment of patients with recurrent head and neck squamous cell carcinomaDoug Villaret, Bonnie Glisson, Daniel Kenady, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 16, 2002
Clinical significance of poor CD3 response in head and neck cancerTerry Y Shibuya, Nghia Nugyen, Christine E McLaren, et al.Pageof 6